CD19 and diffuse large B-cell lymphoma: Apart from loncastuximab tesirine, two other anti-CD19 ADC have been evaluated in clinical trials for DLBCL patients, namely denintuzumab mafodotin and coltuximab ravtansine, but their development has been terminated.